Quick Answer
Entrada Therapeutics, Inc. reported Stockholders Equity of $306.13 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -28.6% in Stockholders Equity from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$20.12 million | Q2 2020: -$26.14 million | Q3 2020: -$33.05 million | Q1 2021: -$49.67 million | Q2 2021: -$59.01 million | Q3 2021: -$72.59 million | Q1 2022: $277.39 million | Q2 2022: $256.04 million | Q3 2022: $233.22 million | Q1 2023: $229.61 million | Q2 2023: $206.91 million | Q3 2023: $246.66 million | Q1 2024: $269.37 million | Q2 2024: $429.93 million | Q3 2024: $422.45 million | Q1 2025: $417.26 million | Q2 2025: $379.51 million | Q3 2025: $340.72 million.
- Over the full 7 years of available data (2019 to 2025), Entrada Therapeutics, Inc.'s Stockholders Equity has grown by 2,072.8%.
- Historical annual values: Fiscal year 2025: $306.13 million | Fiscal year 2024: $428.68 million | Fiscal year 2023: $242.36 million | Fiscal year 2022: $212.55 million | Fiscal year 2021: $298.72 million | Fiscal year 2020: -$41.49 million | Fiscal year 2019: -$15.52 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: